Screener
ClearPoint Neuro CLPT Accounts Receivable, Credit Loss Expense (Reversal)
Accounts Receivable, Credit Loss Expense (Reversal) at other companies
Other financials
Where this comes from
Reported directly by ClearPoint Neuro in its filing.
Tagged under the XBRL concept us-gaap:ProvisionForDoubtfulAccounts.
The source filing: ClearPoint Neuro’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221890
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(9,552) | $(6,026) |
| Adjustments to reconcile net loss to net cash flows from operating activities: | ||
| Allowance for credit losses (recoveries) | (95) | 217 |
| Depreciation and amortization | 86 | 103 |
| Amortization of intangible assets | 504 | — |
| Share-based compensation | 2,218 | 1,908 |
| Payment-in-kind interest | 525 | — |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is ClearPoint Neuro's accounts receivable, credit loss expense (reversal)?
- ClearPoint Neuro (CLPT) reported accounts receivable, credit loss expense (reversal) of -$95K in Q1 2026.
- How has ClearPoint Neuro's accounts receivable, credit loss expense (reversal) changed year-over-year?
- ClearPoint Neuro's accounts receivable, credit loss expense (reversal) decreased by 143.8% year-over-year, from $217K to -$95K.
Ask your AI about ClearPoint Neuro's accounts receivable, credit loss expense (reversal).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude